<italic style="font-style: italic">SPAG</italic>6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药

潘施睿; 罗洁; 罗菁; 尹家秀; 赵海秋; 苏榕; 刘林

doi:10.16016/j.2097-0927.202407086

您当前的位置：

首页 >

文章列表页 >

SPAG6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药

基础医学 | 更新时间：2026-01-09

- SPAG6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药
- SPAG6 promotes proliferation and drug resistance in B-ALL cells through the NF-κB/ TNF-α pathway
- 陆军军医大学学报 2024年46卷第24期页码：2723-2735
- 作者机构：
  
  1.400016 重庆，重庆医科大学附属第一医院血液内科
  2.400016 重庆，重庆医科大学实验研究中心
- 作者简介：
  
  [刘林，E-mail：liulin@cqmu.edu.cnLIU Lin, E-mail: liulin@cqmu.edu.cn
- 基金信息：
  
  国家自然科学基金面上项目(82070130);利益冲突声明本文所有作者均声明不存在利益冲突。
- DOI：10.16016/j.2097-0927.202407086
  中图分类号： R341;R730.23;R733.7
- 收稿：2024-07-22，
  
  修回：2024-11-15，
  
  纸质出版：2024-12-30
- 稿件说明：
移动端阅览
潘施睿, 罗洁, 罗菁, 等. SPAG6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药[J]. 陆军军医大学学报, 2024,46(24):2723-2735.

Shirui PAN, Jie LUO, Jing LUO, et al. SPAG6 promotes proliferation and drug resistance in B-ALL cells through the NF-κB/ TNF-α pathway[J]. Journal of Army Medical University, 2024, 46(24): 2723-2735.
潘施睿, 罗洁, 罗菁, 等. SPAG6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药[J]. 陆军军医大学学报, 2024,46(24):2723-2735. DOI： 10.16016/j.2097-0927.202407086.

Shirui PAN, Jie LUO, Jing LUO, et al. SPAG6 promotes proliferation and drug resistance in B-ALL cells through the NF-κB/ TNF-α pathway[J]. Journal of Army Medical University, 2024, 46(24): 2723-2735. DOI： 10.16016/j.2097-0927.202407086.

摘要

目的

探究精子相关抗原6(sperm-associated antigen 6

SPAG

6)对急性B淋巴细胞白血病(B-cell acute lymphoblastic leukemia

B-ALL)细胞增殖及耐药的相关作用机制。

方法

纳入2019年1月至2023年12月重庆医科大学附属第一医院血液内科收治的56例B-ALL患者和15例缺铁性贫血(iron-deficiency anemia

IDA)患者

将B-ALL患者作为实验组

IDA患者作为对照组。收集B-ALL患者骨髓组织并提取其骨髓单个核细胞

RT-qPCR检测

SPAG

6的mRNA表达情况并对B-ALL患者进行分层分析

分为新诊断病例组(New-diag)、完全缓解组(complete remission

CR)、微小残留病(minimal residual disease

MRD)阳性组(MRD+)和复发组(Relapse); 使用慢病毒感染构建

SPAG

6基因过表达(

SPAG

6-OE)和敲低(

SPAG

6-KD)的B-ALL细胞系

CCK-8和基于甲基纤维素的集落形成实验检测各组细胞的存活、增殖和成集落潜能; CCK-8检测化疗药物柔红霉素(daunorubicin

DNR)和甲氨蝶呤(methotrexate

MTX)处理后细胞存活率(可反映其药物敏感性和IC50);从TARGET数据库获取B-ALL患者的mRNA-seq图谱

通过基因集富集分析(gene set enrichment analysis

GSEA)探索与

SPAG

6相关的信号通路并进行实验验证; NF-κB激活剂PMA和抑制剂BAY-11-7082作用后

通过CCK-8检测细胞存活率以及对化疗药物的敏感性

Western blot检测通路相关蛋白NF-κB P65、p-NF-κB P65、TNF-α等的表达情况; 构建小鼠异种移植瘤模型

-/+敲低

SPAG

6组腹腔注射生理盐水作为对照组

-/+敲低

SPAG

6组腹腔注射DNR作为实验组

免疫组化检测NF-κB信号通路在组织中的表达情况。

结果

B-ALL患者

SPAG

6 mRNA表达明显高于IDA组(

0.05)

同时与CR组比较

SPAG

6高表达于MRD+组(

=0.001)和复发组(

=0.003)。对比不同

SPAG

6表达水平细胞对化疗药物的反应

CCK-8实验证实

SPAG

6促进B-ALL细胞增殖(

0.05)

并降低其对DNR和MTX的敏感性(

均

0.05);机制上

GSEA结果提示NF-κB通路在B-ALL富集

实验证实

SPAG

6通过激活NF-κB/TNF-α通路增强B-ALL细胞对化疗药物的耐药。在体内

敲低

SPAG

6明显减小小鼠移植瘤体积(

0.05)

并在联合DNR治疗组观察到肿瘤体积额外减小(

0.05)。此外

免疫组化结果提示联合DNR治疗组NF-κB P65和p-IKBα水平降低。

结论

SPAG

6通过NF-κB/TNF-α通路促进B-ALL细胞增殖

降低其化疗敏感性

提示

SPAG

6与B-ALL患者的治疗效果和预后密切相关。

Abstract

Objective

To elucidate the underlying mechanisms of sperm-associated antigen 6(

SPAG

6) in the proliferation and drug resistance of B-cell acute lymphoblastic leukemia (B-ALL).

Methods

A total of 56 B-ALL patients and 15 iron-deficiency anemia (IDA) patients admitted in the First Affiliated Hospital of Chongqing Medical University from January 2019 to December 2023 were recruited and served as the experimental and control groups

respectively.Bone marrow mononuclear cells (BMMNCs) were derived from the bone marrow tissues of the experimental group.According to the results of qRT-PCR for the expression of

SPAG

6 in the obtained BMMNCs

the B-ALL patients were stratified into newly-diagnosed (New-diag) group

complete remission (CR) group

minimal residual disease Possitive (MRD+) group

and relapse group.Lentiviral vectors were used to construct B-ALL cells with

SPAG

6 overexpression and knockdown.CCK-8 assay and methylcellulose-based colony formation experiment were employed to assess the survival

proliferation

and clonogenic potential of the cells with varying

SPAG

6 expression levels.After f B-ALL cells were treated with the chemotherapeutic drugs

daunorubicin (DNR) and methotrexate (MTX)

CCK-8 assay

flow cytometry and Western blot analysis were applied to detect cell viability (drug sensitivity and IC50)

cell apoptosis

and protein levels of apoptosis-related molecules Bax

Caspase-3 and Bcl-2

respectively.The mRNA-seq profiles of B-ALL patients were obtained from the TARGET database

and gene set enrichment analysis (GSEA) was conducted to explore

SPAG

6-associated signaling pathways

which were subsequently validated experimentally.After treatment with the NF-κB agonist Phorbol 12-myristate 13-acetate (PMA) and the antagonist BAY-11-7082

cell viabi

lity and sensitivity to chemotherapeutic drugs were assessed with CCK-8 assay

and the expression of pathway-related proteins NF-κB P65

p-NF-κB p65

IKBα

p-IKBα

TNF-α

and EPO was detected by Western blot analysis.A mouse xenograft tumor model was constructed in

SPAG

-/+

knockdown mice to observe the effect of DNR on tumor growth and the expression of the NF-κB signaling pathway in the tumor tissues with immunohistochemical assay.

Results

The mRNA level of

SPAG

6 was significantly higher in the B-ALL patients (

0.05)

and in the MRD group (

=0.001) and R group (

=0.003) than the CR group.

SPAG

6 overexpression and knockdown in B-ALL cells confirmed that

SPAG

6 promoted the proliferation (

0.05) and decreased the sensitivity to DNR and MTX (

0.05).

SPAG

6 resisted chemotherapy-induced apoptosis in B-ALL cells by down-regulating pro-apoptotic proteins Bax and Caspase-3(

0.05)

and up-regulating the expression of anti-apoptotic protein Bcl-2(

0.05).GSEA analysis suggested that the NF-κB pathway was enriched in B-ALL cells

and our experiments confirmed that

SPAG

6 enhanced the chemoresistance of B-ALL cells to chemotherapy by activating the NF-κB/TNF-α pathway.In

in vivo

experiments

knocking

SPAG

6 down significantly reduced the volume of transplanted tumors (

0.05)

and an additional decrease in tumor growth was observed in the DNR-combined treatment group (

0.05)

with reduced levels of NF-κB P65 and p-IKBα by immunohistochemical assay.

Conclusion

SPAG

6 promotes the proliferation of B-ALL cells and reduces their chemosensitivity

via

the NF-κB/TNF-α pathway

suggesting a close association

SPAG

6 with the therapeutic outcomes and prognosis in B-ALL patients.

关键词

Keywords

references

MALARD F, MOHTY M. Acute lymphoblasti cleukaemia[J]. Lancet, 2020, 395(10230): 1146-1162. DOI: 10.1016/S0140-6736(19)33018-1.

MULLIGHAN C G. Molecular genetics of B-precursor acute lymphoblastic leukemia[J]. J Clin Invest, 2012, 122(10): 3407-3415. DOI: 10.1172/JCI61203.

GÖKBUGET N, HOELZER D. Treatment of adult acute lymphoblastic leukemia[J]. Semin Hematol, 2009, 46(1): 64-75. DOI: 10.1053/j.seminhematol.2008.09.003.

LITZOW M R. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults[J]. Drugs, 2011, 71(4): 415-442. DOI: 10.2165/11588950-000000000-00000.

GOLDSTONEA H, RICHARDS S M, LAZARUS H M, et al . In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international all trial (mrc ukall xii/ecog E2993)[J ] . Blood, 2008, 111(4): 1827-1833. DOI: 10.1182/blood-2007-10-116582.

RIBERA J M, ORIOL A. Acute lymphoblastic leukemia in adolescents and young adults[J]. Hematol Oncol Clin North Am, 2009, 23(5): 1033-1042. DOI: 10.1016/j.hoc.2009.07.002.

YOSHIMURA S, LI Z H, GOCHO Y, et al . Impact of age on pharmacogenomics and treatment outcomes of B-cell acute lymphoblastic leukemia[J ] . J Clin Oncol, 2024, 42(29): 3478-3490. DOI: 10.1200/JCO.24.00500.

LI W, MUKHERJEE A, WU J H, et al . Sperm associated antigen 6 ( SPAG 6) regulates fibroblast cell growth, morphology, migration and ciliogenesis[J ] . Sci Rep, 2015, 5: 16506. DOI: 10.1038/srep16506..

ALTENBERGER C, HELLER G, ZIEGLER B, et al . SPAG 6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers[J ] . Mol Cancer, 2017, 16(1): 1. DOI: 10.1186/s12943-016-0568-5..

YANG B H, WANG L, LUO X H, et al . SPAG 6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis[J ] . Int J Oncol, 2015, 46(2): 649-656. DOI: 10.3892/ijo.2014.2768..

SILINA K, ZAYAKIN P, KALNINA Z, et al . Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients[J ] . J Immunother, 2011, 34(1): 28-44. DOI: 10.1097/CJI.0b013e3181fb64fa.

MU J, YUAN P, LUO J, et al . Upregulated SPAG 6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression[J ] . Blood Adv, 2022, 6(18): 5379-5394. DOI: 10.1182/blood advances.2021006920..

ZHAO B B, YIN J X, DING L, et al . SPAG 6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia[J ] . Int J Hematol, 2024, 119(2): 119-129. DOI: 10.1007/s12185-023-03684-x..

YU H, LIN L B, ZHANG Z Q, et al . Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study[J ] . Signal Transduct Target Ther, 2020, 5(1): 209. DOI: 10.1038/s41392-020-00312-6.

YANG L Q, SHI P F, ZHAO G C, et al . Targeting cancer stem cell pathways for cancer therapy[J ] . Signal Transduct Target Ther, 2020, 5(1): 8. DOI: 10.1038/s41392-020-0110-5.

DIDONATO J A, MERCURIO F, KARIN M. NF-κB and the link between inflammation and cancer[J]. Immunol Rev, 2012, 246(1): 379-400. DOI: 10.1111/j.1600-065X.2012.01099.x.

DI FRANCESCO B, VERZELLA D, CAPECE D, et al . NF-κB: a druggable target in acute myeloid leukemia[J ] . Cancers, 2022, 14(14): 3557. DOI: 10.3390/cancers14143557.

ZHAI J, SHEN J J, XIE G P, et al . Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer[J ] . Cancer Lett, 2019, 454: 37-43. DOI: 10.1016/j.canlet.2019.04.002.

PAVITRA E, KANCHARLA J, GUPTA V K, et al . The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy[J ] . Biomed Pharmacother, 2023, 163: 114822. DOI: 10.1016/j.biopha.2023.114822.

AZUMA K, IKEDA K, SUZUKI T, et al . TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer[J ] . Proc Natl Acad Sci U S A, 2021, 118(35): e2100784118. DOI: 10.1073/pnas.2100784118..

YUAN Z T, LIANG X, ZHAN Y P, et al . Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer[J ] . Br J Cancer, 2020, 122(9): 1342-1353. DOI: 10.1038/s41416-020-0783-0..

ZHU J L, TONG H, SUN Y, et al . Ythdf1 promotes bladder cancer cell proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR axis[J ] . Int J Mol Sci, 2023, 24(8): 6905. DOI: 10.3390/ijms24086905..

JIANG M, CHEN Y, DENG L L, et al . Upregulation of SPAG6 in myelodysplastic syndrome: knockdown inhibits cell proliferation via AKT/FOXO signaling pathway[J ] . DNA Cell Biol, 2019, 38(5): 476-484. DOI: 10.1089/dna.2018.4521..

LI X X, YANG B H, WANG L, et al . SPAG 6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes[J ] . Oncol Rep, 2017, 37(5): 2839-2846. DOI: 10.3892/or.2017.5540..

YIN J X, LI X X, ZHANG Z L, et al . SPAG 6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM-1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo [J ] . Int J Oncol, 2018, 53(1): 297-306. DOI: 10.3892/ijo.2018.4390..

ZHANG M, LUO J, LUO X H, et al . SPAG 6 silencing induces autophagic cell death in SKM-1 cells via the AMPK/mTOR/ULK1 signaling pathway[J ] . Oncol Lett, 2020, 20(1): 551-560. DOI: 10.3892/ol.2020.11607..

DING L, LUO J, DU J, et al . Upregulated SPAG 6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon-α response in BCR: ABL1 negative myeloproliferative neoplasms[J ] . Cancer Sci, 2023, 114(11): 4445-4458. DOI: 10.1111/cas.15950..

LUO J, MU J, ZHANG M, et al . SPAG 6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model[J ] . Leuk Lymphoma, 2021, 62(9): 2242-2252. DOI: 10.1080/10428194.2021.1913148..

SUN S C. The non-canonical NF-κB pathway in immunity and inflammation[J]. Nat Rev Immunol, 2017, 17: 545-558. DOI: 10.1038/nri.2017.52.

HUYNH M, PAK C, MARKOVINA S, et al . Hyaluronan and proteoglycan link protein 1 ( HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma[J ] . J Biol Chem, 2018, 293(7): 2452-2465. DOI: 10.1074/jbc.RA117.000667.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

超低浓度二甲基亚砜促进皮肤成纤维细胞增殖作用及机制研究

谷胱甘肽过氧化物酶7通过PI3K-AKT通路调控肝癌细胞增殖和衰老

缺氧诱导因子-1α纳米抑制剂的构建及在逆转结直肠癌细胞化疗耐药中的应用

静息期精原前体细胞Rb1基因敲除致精原干细胞特化异常机制初探

SPAG6通过NF-κB/TNF-α途径促进B-ALL细胞增殖和耐药

SPAG6 promotes proliferation and drug resistance in B-ALL cells through the NF-κB/ TNF-α pathway

DOI：10.16016/j.2097-0927.202407086

摘要

Abstract

关键词

Keywords

references